一项评估HL-085胶囊联合维莫非尼治疗BRAF V600E突变不可切除局部晚期或转移性非小细胞肺癌(NSCLC)患者有效性和安全性的单臂、开放性、多中心 Ⅱ 期临床研究
[Translation] A single-arm, open-label, multicenter Phase II clinical study to evaluate the efficacy and safety of HL-085 capsule combined with vemurafenib in the treatment of patients with BRAF V600E mutation-unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC)
评价HL-085联合维莫非尼治疗BRAF V600E突变不可切除局部晚期或转移性NSCLC患者的客观缓解率(ORR)
[Translation] To evaluate the objective response rate (ORR) of HL-085 combined with vemurafenib in patients with unresectable locally advanced or metastatic NSCLC with BRAF V600E mutation
评价妥拉美替尼胶囊对比研究者选择的联合化疗在既往接受过免疫治疗的NRAS突变的晚期黑色素瘤患者中的有效性和安全性的开放、随机对照、多中心III期临床研究
[Translation] An open, randomized, controlled, multicenter phase III clinical study to evaluate the efficacy and safety of tolametinib capsules versus investigator-selected combination chemotherapy in patients with NRAS-mutated advanced melanoma who have previously received immunotherapy
评价妥拉美替尼胶囊对比研究者选择的联合化疗在既往接受过免疫治疗的NRAS突变的晚期黑色素瘤患者中的无进展生存期(PFS)
[Translation] To evaluate the progression-free survival (PFS) of tolametinib capsules versus investigator's choice of combination chemotherapy in patients with NRAS-mutated advanced melanoma who have received prior immunotherapy
一项评价妥拉美替尼联合维莫非尼治疗BRAFV600E突变转移性结直肠癌患者有效性和安全性的随机、对照、开放性、多中心Ⅲ期临床研究
[Translation] A randomized, controlled, open-label, multicenter phase III clinical study to evaluate the efficacy and safety of tolametinib combined with vemurafenib in the treatment of patients with BRAFV600E mutation metastatic colorectal cancer
比较妥拉美替尼联合维莫非尼与研究者选择治疗(以化疗为基础)的有效性,基于独立影像评估委员会(IRRC)评估确定的无进展生存期(IRRC-PFS)。
[Translation] To compare the effectiveness of tolametinib plus vemurafenib with investigator's choice of treatment (chemotherapy-based), based on progression-free survival determined by independent radiographic review committee (IRRC) assessment (IRRC-PFS).
100 Clinical Results associated with Binjiang Pharma, Inc.
0 Patents (Medical) associated with Binjiang Pharma, Inc.
100 Deals associated with Binjiang Pharma, Inc.
100 Translational Medicine associated with Binjiang Pharma, Inc.